Ignite Creation Date:
2025-12-25 @ 12:32 AM
Ignite Modification Date:
2026-02-20 @ 1:44 PM
Study NCT ID:
NCT02238067
Status:
COMPLETED
Last Update Posted:
2017-03-24
First Post:
2014-09-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Survey on Anemia Therapy in Participants With Chronic Kidney Disease (CKD) Not on Dialysis
Sponsor:
Organization:
Raw JSON
{'hasResults': True, 'derivedSection': {'miscInfoModule': {'versionHolder': '2025-12-24'}, 'conditionBrowseModule': {'meshes': [{'id': 'D051436', 'term': 'Renal Insufficiency, Chronic'}], 'ancestors': [{'id': 'D051437', 'term': 'Renal Insufficiency'}, {'id': 'D007674', 'term': 'Kidney Diseases'}, {'id': 'D014570', 'term': 'Urologic Diseases'}, {'id': 'D052776', 'term': 'Female Urogenital Diseases'}, {'id': 'D005261', 'term': 'Female Urogenital Diseases and Pregnancy Complications'}, {'id': 'D000091642', 'term': 'Urogenital Diseases'}, {'id': 'D052801', 'term': 'Male Urogenital Diseases'}, {'id': 'D002908', 'term': 'Chronic Disease'}, {'id': 'D020969', 'term': 'Disease Attributes'}, {'id': 'D010335', 'term': 'Pathologic Processes'}, {'id': 'D013568', 'term': 'Pathological Conditions, Signs and Symptoms'}]}}, 'resultsSection': {'moreInfoModule': {'pointOfContact': {'email': 'genentech@druginfo.com', 'phone': '800-821-8590', 'title': 'Medical Communications', 'organization': 'Hoffmann-La Roche'}, 'certainAgreement': {'otherDetails': "The Study being conducted under this Agreement is part of the Overall Study. Investigator is free to publish in reputable journals or to present at professional conferences the results of the Study, but only after the first publication or presentation that involves the Overall Study. The Sponsor may request that Confidential Information be deleted and/or the publication be postponed in order to protect the Sponsor's intellectual property rights.", 'restrictionType': 'OTHER', 'piSponsorEmployee': False, 'restrictiveAgreement': True}, 'limitationsAndCaveats': {'description': 'The study was completed as defined in the protocol. Only 196 participants (out of planned 400) were enrolled due to slow recruitment during the study period.'}}, 'adverseEventsModule': {'timeFrame': 'From Baseline up to Month 6', 'description': 'Non-serious adverse events (AEs) were not collected in this study.', 'eventGroups': [{'id': 'EG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.', 'otherNumAtRisk': 0, 'otherNumAffected': 0, 'seriousNumAtRisk': 196, 'seriousNumAffected': 3}], 'seriousEvents': [{'term': 'Upper gastrointestinal haemorrhage', 'stats': [{'groupId': 'EG000', 'numAtRisk': 196, 'numAffected': 1}], 'organSystem': 'Gastrointestinal disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Cardiac failure congestive', 'stats': [{'groupId': 'EG000', 'numAtRisk': 196, 'numAffected': 1}], 'organSystem': 'Cardiac disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Chronic kidney disease', 'stats': [{'groupId': 'EG000', 'numAtRisk': 196, 'numAffected': 1}], 'organSystem': 'Renal and urinary disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}, {'term': 'Death', 'stats': [{'groupId': 'EG000', 'numAtRisk': 196, 'numAffected': 1}], 'organSystem': 'General disorders', 'assessmentType': 'NON_SYSTEMATIC_ASSESSMENT', 'sourceVocabulary': 'MedDRA 18.1'}], 'frequencyThreshold': '0'}, 'outcomeMeasuresModule': {'outcomeMeasures': [{'type': 'PRIMARY', 'title': 'Percentage of Participants by ESA Types at Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '196', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Mircera', 'categories': [{'measurements': [{'value': '51.5', 'groupId': 'OG000', 'lowerLimit': '44.3', 'upperLimit': '58.7'}]}]}, {'title': 'Recormon', 'categories': [{'measurements': [{'value': '17.3', 'groupId': 'OG000', 'lowerLimit': '12.3', 'upperLimit': '23.4'}]}]}, {'title': 'Eprex', 'categories': [{'measurements': [{'value': '10.7', 'groupId': 'OG000', 'lowerLimit': '6.8', 'upperLimit': '15.9'}]}]}, {'title': 'Aranesp', 'categories': [{'measurements': [{'value': '20.4', 'groupId': 'OG000', 'lowerLimit': '15.0', 'upperLimit': '26.7'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type was reported.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled participants'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants by ESA Types at Month 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '151', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Mircera', 'categories': [{'measurements': [{'value': '43.7', 'groupId': 'OG000', 'lowerLimit': '35.7', 'upperLimit': '52.0'}]}]}, {'title': 'Recormon', 'categories': [{'measurements': [{'value': '19.2', 'groupId': 'OG000', 'lowerLimit': '13.3', 'upperLimit': '26.4'}]}]}, {'title': 'Eprex', 'categories': [{'measurements': [{'value': '12.6', 'groupId': 'OG000', 'lowerLimit': '7.7', 'upperLimit': '19.0'}]}]}, {'title': 'Aranesp', 'categories': [{'measurements': [{'value': '24.5', 'groupId': 'OG000', 'lowerLimit': '17.9', 'upperLimit': '32.2'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Month 6', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type was reported.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled participants who completed the questionnaire at Month 6'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants by Frequency of ESA Use at Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '195', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Three times a week', 'categories': [{'measurements': [{'value': '2.6', 'groupId': 'OG000', 'lowerLimit': '0.8', 'upperLimit': '5.9'}]}]}, {'title': 'Twice a week', 'categories': [{'measurements': [{'value': '7.2', 'groupId': 'OG000', 'lowerLimit': '4.0', 'upperLimit': '11.8'}]}]}, {'title': 'Once a week', 'categories': [{'measurements': [{'value': '14.9', 'groupId': 'OG000', 'lowerLimit': '10.2', 'upperLimit': '20.7'}]}]}, {'title': 'Every 2 weeks', 'categories': [{'measurements': [{'value': '26.2', 'groupId': 'OG000', 'lowerLimit': '20.1', 'upperLimit': '32.9'}]}]}, {'title': 'Every 4 weeks', 'categories': [{'measurements': [{'value': '38.5', 'groupId': 'OG000', 'lowerLimit': '31.6', 'upperLimit': '45.7'}]}]}, {'title': 'Other', 'categories': [{'measurements': [{'value': '10.8', 'groupId': 'OG000', 'lowerLimit': '6.8', 'upperLimit': '16.0'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). Percentage of participants by each frequency of ESA use was reported.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled participants. Number of participants analyzed = participants evaluable for this outcome measure.'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants by Frequency of ESA Use at Month 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '151', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Three times a week', 'categories': [{'measurements': [{'value': '1.3', 'groupId': 'OG000', 'lowerLimit': '0.2', 'upperLimit': '4.7'}]}]}, {'title': 'Twice a week', 'categories': [{'measurements': [{'value': '4.0', 'groupId': 'OG000', 'lowerLimit': '1.5', 'upperLimit': '8.4'}]}]}, {'title': 'Once a week', 'categories': [{'measurements': [{'value': '15.9', 'groupId': 'OG000', 'lowerLimit': '10.5', 'upperLimit': '22.7'}]}]}, {'title': 'Every 2 weeks', 'categories': [{'measurements': [{'value': '25.2', 'groupId': 'OG000', 'lowerLimit': '18.5', 'upperLimit': '32.9'}]}]}, {'title': 'Every 4 weeks', 'categories': [{'measurements': [{'value': '39.1', 'groupId': 'OG000', 'lowerLimit': '31.2', 'upperLimit': '47.3'}]}]}, {'title': 'Other', 'categories': [{'measurements': [{'value': '14.6', 'groupId': 'OG000', 'lowerLimit': '9.4', 'upperLimit': '21.2'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Month 6', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). Percentage of participants by each frequency of ESA use was reported.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': 'All enrolled participants who completed the questionnaire at Month 6'}, {'type': 'PRIMARY', 'title': 'Percentage of Participants by Frequency and Types of ESA Used at Baseline', 'denoms': [{'units': 'Participants', 'counts': [{'value': '195', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Mircera : Three times a week (n=100)', 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera : Twice a week (n=100)', 'categories': [{'measurements': [{'value': '4.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera : Once a week (n=100)', 'categories': [{'measurements': [{'value': '1.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera : Every 2 weeks (n=100)', 'categories': [{'measurements': [{'value': '26.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera : Every 4 weeks (n=100)', 'categories': [{'measurements': [{'value': '67.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera : Other (n=100)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon : Three times a week (n=34)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon : Twice a week (n=34)', 'categories': [{'measurements': [{'value': '17.6', 'groupId': 'OG000'}]}]}, {'title': 'Recormon : Once a week (n=34)', 'categories': [{'measurements': [{'value': '38.2', 'groupId': 'OG000'}]}]}, {'title': 'Recormon : Every 2 weeks (n=34)', 'categories': [{'measurements': [{'value': '17.6', 'groupId': 'OG000'}]}]}, {'title': 'Recormon : Every 4 weeks (n=34)', 'categories': [{'measurements': [{'value': '5.9', 'groupId': 'OG000'}]}]}, {'title': 'Recormon : Other (n=34)', 'categories': [{'measurements': [{'value': '20.6', 'groupId': 'OG000'}]}]}, {'title': 'Eprex : Three times a week (n=21)', 'categories': [{'measurements': [{'value': '9.5', 'groupId': 'OG000'}]}]}, {'title': 'Eprex : Twice a week (n=21)', 'categories': [{'measurements': [{'value': '9.5', 'groupId': 'OG000'}]}]}, {'title': 'Eprex : Once a week (n=21)', 'categories': [{'measurements': [{'value': '42.9', 'groupId': 'OG000'}]}]}, {'title': 'Eprex : Every 2 weeks (n=21)', 'categories': [{'measurements': [{'value': '9.5', 'groupId': 'OG000'}]}]}, {'title': 'Eprex : Every 4 weeks (n=21)', 'categories': [{'measurements': [{'value': '4.8', 'groupId': 'OG000'}]}]}, {'title': 'Eprex : Other (n=21)', 'categories': [{'measurements': [{'value': '23.8', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp : Three times a week (n=40)', 'categories': [{'measurements': [{'value': '2.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp : Twice a week (n=40)', 'categories': [{'measurements': [{'value': '5.0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp : Once a week (n=40)', 'categories': [{'measurements': [{'value': '15.0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp : Every 2 weeks (n=40)', 'categories': [{'measurements': [{'value': '42.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp : Every 4 weeks (n=40)', 'categories': [{'measurements': [{'value': '12.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp : Other (n=40)', 'categories': [{'measurements': [{'value': '22.5', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type and each frequency of ESA use was reported.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "All enrolled participants. Number of participants analyzed = participants evaluable for this outcome measure. Here 'n' signifies number of participants evaluable for specified categories."}, {'type': 'PRIMARY', 'title': 'Percentage of Participants by Frequency and Types of ESA Used at Month 6', 'denoms': [{'units': 'Participants', 'counts': [{'value': '151', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Mircera : Three times a week (n=66)', 'categories': [{'measurements': [{'value': '1.5', 'groupId': 'OG000'}]}]}, {'title': 'Mircera : Twice a week (n=66)', 'categories': [{'measurements': [{'value': '1.5', 'groupId': 'OG000'}]}]}, {'title': 'Mircera : Once a week (n=66)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera : Every 2 weeks (n=66)', 'categories': [{'measurements': [{'value': '18.2', 'groupId': 'OG000'}]}]}, {'title': 'Mircera : Every 4 weeks (n=66)', 'categories': [{'measurements': [{'value': '71.2', 'groupId': 'OG000'}]}]}, {'title': 'Mircera : Other (n=66)', 'categories': [{'measurements': [{'value': '7.6', 'groupId': 'OG000'}]}]}, {'title': 'Recormon : Three times a week (n=29)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon : Twice a week (n=29)', 'categories': [{'measurements': [{'value': '10.3', 'groupId': 'OG000'}]}]}, {'title': 'Recormon : Once a week (n=29)', 'categories': [{'measurements': [{'value': '27.6', 'groupId': 'OG000'}]}]}, {'title': 'Recormon : Every 2 weeks (n=29)', 'categories': [{'measurements': [{'value': '37.9', 'groupId': 'OG000'}]}]}, {'title': 'Recormon : Every 4 weeks (n=29)', 'categories': [{'measurements': [{'value': '6.9', 'groupId': 'OG000'}]}]}, {'title': 'Recormon : Other (n=29)', 'categories': [{'measurements': [{'value': '17.2', 'groupId': 'OG000'}]}]}, {'title': 'Eprex : Three times a week (n=19)', 'categories': [{'measurements': [{'value': '5.3', 'groupId': 'OG000'}]}]}, {'title': 'Eprex : Twice a week (n=19)', 'categories': [{'measurements': [{'value': '5.3', 'groupId': 'OG000'}]}]}, {'title': 'Eprex : Once a week (n=19)', 'categories': [{'measurements': [{'value': '47.4', 'groupId': 'OG000'}]}]}, {'title': 'Eprex : Every 2 weeks (n=19)', 'categories': [{'measurements': [{'value': '15.8', 'groupId': 'OG000'}]}]}, {'title': 'Eprex : Every 4 weeks (n=19)', 'categories': [{'measurements': [{'value': '5.3', 'groupId': 'OG000'}]}]}, {'title': 'Eprex : Other (n=19)', 'categories': [{'measurements': [{'value': '21.1', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp : Three times a week (n=37)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp : Twice a week (n=37)', 'categories': [{'measurements': [{'value': '2.7', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp : Once a week (n=37)', 'categories': [{'measurements': [{'value': '18.9', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp : Every 2 weeks (n=37)', 'categories': [{'measurements': [{'value': '32.4', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp : Every 4 weeks (n=37)', 'categories': [{'measurements': [{'value': '24.3', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp : Other (n=37)', 'categories': [{'measurements': [{'value': '21.6', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Month 6', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type and each frequency of ESA use was reported.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "All enrolled participants who completed the questionnaire at Month 6. Here 'n' signifies number of participants evaluable for specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants by Different CKD Stages', 'denoms': [{'units': 'Participants', 'counts': [{'value': '196', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Stage 1 : Baseline (n=196)', 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000'}]}]}, {'title': 'Stage 1 : Month 6 (n=151)', 'categories': [{'measurements': [{'value': '1.3', 'groupId': 'OG000'}]}]}, {'title': 'Stage 2 : Baseline (n=196)', 'categories': [{'measurements': [{'value': '10.2', 'groupId': 'OG000'}]}]}, {'title': 'Stage 2 : Month 6 (n=151)', 'categories': [{'measurements': [{'value': '13.9', 'groupId': 'OG000'}]}]}, {'title': 'Stage 3 : Baseline (n=196)', 'categories': [{'measurements': [{'value': '37.8', 'groupId': 'OG000'}]}]}, {'title': 'Stage 3 : Month 6 (n=151)', 'categories': [{'measurements': [{'value': '41.7', 'groupId': 'OG000'}]}]}, {'title': 'Stage 4 : Baseline (n=196)', 'categories': [{'measurements': [{'value': '37.8', 'groupId': 'OG000'}]}]}, {'title': 'Stage 4 : Month 6 (n=151)', 'categories': [{'measurements': [{'value': '30.5', 'groupId': 'OG000'}]}]}, {'title': 'Stage 5 : Baseline (n=196)', 'categories': [{'measurements': [{'value': '12.2', 'groupId': 'OG000'}]}]}, {'title': 'Stage 5 : Month 6 (n=151)', 'categories': [{'measurements': [{'value': '12.6', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. CKD stages were based on participant's answer to the survey question. No specific method of assessment for CKD stage was specified. Percentage of participants with each CKD stage was reported.", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants by Different Injection Administration Modes', 'denoms': [{'units': 'Participants', 'counts': [{'value': '196', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Independently : Baseline (n=196)', 'categories': [{'measurements': [{'value': '18.4', 'groupId': 'OG000'}]}]}, {'title': 'Independently : Month 6 (n=151)', 'categories': [{'measurements': [{'value': '23.2', 'groupId': 'OG000'}]}]}, {'title': 'By a family member : Baseline (n=196)', 'categories': [{'measurements': [{'value': '16.8', 'groupId': 'OG000'}]}]}, {'title': 'By a family member : Month 6 (n=151)', 'categories': [{'measurements': [{'value': '17.9', 'groupId': 'OG000'}]}]}, {'title': 'Nurse at home : Baseline (n=196)', 'categories': [{'measurements': [{'value': '3.6', 'groupId': 'OG000'}]}]}, {'title': 'Nurse at home : Month 6 (n=151)', 'categories': [{'measurements': [{'value': '3.3', 'groupId': 'OG000'}]}]}, {'title': 'Nurse at the clinic : Baseline (n=196)', 'categories': [{'measurements': [{'value': '58.2', 'groupId': 'OG000'}]}]}, {'title': 'Nurse at the clinic : Month 6 (n=151)', 'categories': [{'measurements': [{'value': '52.3', 'groupId': 'OG000'}]}]}, {'title': 'Other: Baseline (n=196)', 'categories': [{'measurements': [{'value': '3.1', 'groupId': 'OG000'}]}]}, {'title': 'Other : Month 6 (n=151)', 'categories': [{'measurements': [{'value': '3.3', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked: 'How do you currently inject the anemia treatment?' and reported any of the 5 possible answers: Independently, by a family member, nurse at home, nurse at the clinic or other. Percentage of participants with each injection administration modes was reported.", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants With Interest in Learning to Inject Independently', 'denoms': [{'units': 'Participants', 'counts': [{'value': '160', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Baseline (n=160)', 'categories': [{'measurements': [{'value': '6.3', 'groupId': 'OG000', 'lowerLimit': '3.0', 'upperLimit': '11.2'}]}]}, {'title': 'Month 6 (n=116)', 'categories': [{'measurements': [{'value': '4.3', 'groupId': 'OG000', 'lowerLimit': '1.4', 'upperLimit': '9.8'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants responded 'yes' or 'no' to the question: 'Would you be interested in learning to inject independently?' ' Percentage of participants who responded 'yes', was reported.", 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "All enrolled participants who did not inject independently. Here 'n' signifies number of participants evaluable at specified time-points."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants by Need for Improvement in Treatment Frequency', 'denoms': [{'units': 'Participants', 'counts': [{'value': '196', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Score 1 : Baseline (n=196)', 'categories': [{'measurements': [{'value': '94.9', 'groupId': 'OG000', 'lowerLimit': '90.8', 'upperLimit': '97.5'}]}]}, {'title': 'Score 1 : Month 6 (n=151)', 'categories': [{'measurements': [{'value': '96.0', 'groupId': 'OG000', 'lowerLimit': '91.6', 'upperLimit': '98.5'}]}]}, {'title': 'Score 2 : Baseline (n=196)', 'categories': [{'measurements': [{'value': '1.5', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.4'}]}]}, {'title': 'Score 2 : Month 6 (n=151)', 'categories': [{'measurements': [{'value': '1.3', 'groupId': 'OG000', 'lowerLimit': '0.2', 'upperLimit': '4.7'}]}]}, {'title': 'Score 3 : Baseline (n=196)', 'categories': [{'measurements': [{'value': '1.5', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.4'}]}]}, {'title': 'Score 3 : Month 6 (n=151)', 'categories': [{'measurements': [{'value': '1.3', 'groupId': 'OG000', 'lowerLimit': '0.2', 'upperLimit': '4.7'}]}]}, {'title': 'Score 4 : Baseline (n=196)', 'categories': [{'measurements': [{'value': '1.5', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.4'}]}]}, {'title': 'Score 4 : Month 6 (n=151)', 'categories': [{'measurements': [{'value': '0.7', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '3.6'}]}]}, {'title': 'Score 5 : Baseline (n=196)', 'categories': [{'measurements': [{'value': '0.5', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '2.8'}]}]}, {'title': 'Score 5 : Month 6 (n=151)', 'categories': [{'measurements': [{'value': '0.7', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '3.6'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their need for improvement in the frequency of treatment received currently on a 1-5 scale, where 1 represents 'Convenient, there is no need for improvement' and 5 represents 'Improvement is very necessary'. Percentage of participants with each score was reported.", 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type', 'denoms': [{'units': 'Participants', 'counts': [{'value': '196', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Mircera: Score 1: Baseline (n=101)', 'categories': [{'measurements': [{'value': '98.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 2: Baseline (n=101)', 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 3: Baseline (n=101)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 4: Baseline (n=101)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 5: Baseline (n=101)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 1: Baseline (n=34)', 'categories': [{'measurements': [{'value': '94.1', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 2: Baseline (n=34)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 3: Baseline (n=34)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 4: Baseline (n=34)', 'categories': [{'measurements': [{'value': '2.9', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 5: Baseline (n=34)', 'categories': [{'measurements': [{'value': '2.9', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 1: Baseline (n=21)', 'categories': [{'measurements': [{'value': '90.5', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 2: Baseline (n=21)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 3: Baseline (n=21)', 'categories': [{'measurements': [{'value': '9.5', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 4: Baseline (n=21)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 5: Baseline (n=21)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 1: Baseline (n=40)', 'categories': [{'measurements': [{'value': '90.0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 2: Baseline (n=40)', 'categories': [{'measurements': [{'value': '2.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 3: Baseline (n=40)', 'categories': [{'measurements': [{'value': '2.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 4: Baseline (n=40)', 'categories': [{'measurements': [{'value': '5.0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 5: Baseline (n=40)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 1: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 2: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 3: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 4: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 5: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 1: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '96.6', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 2: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 3: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '3.4', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 4: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 5: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 1: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '94.7', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 2: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '5.3', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 3: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 4: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 5: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 1: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '89.2', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 2: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '2.7', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 3: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '2.7', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 4: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '2.7', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 5: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '2.7', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their need for improvement in the frequency of each treatment received currently on a 1-5 scale, where 1 represents 'Convenient, there is no need for improvement' and 5 represents 'improvement is very necessary'. Percentage of participants with each score and ESA type was reported.", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "All enrolled participants. Here 'n' signifies number of participants evaluable for specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants by Preferred Treatment Frequency', 'denoms': [{'units': 'Participants', 'counts': [{'value': '196', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Once a month: Baseline (n=196)', 'categories': [{'measurements': [{'value': '63.8', 'groupId': 'OG000', 'lowerLimit': '56.6', 'upperLimit': '70.5'}]}]}, {'title': 'Once a month: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '49.0', 'groupId': 'OG000', 'lowerLimit': '40.8', 'upperLimit': '57.3'}]}]}, {'title': 'Twice a month: Baseline (n=196)', 'categories': [{'measurements': [{'value': '17.3', 'groupId': 'OG000', 'lowerLimit': '12.3', 'upperLimit': '23.4'}]}]}, {'title': 'Twice a month: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '23.8', 'groupId': 'OG000', 'lowerLimit': '17.3', 'upperLimit': '31.4'}]}]}, {'title': 'Once a week: Baseline (n=196)', 'categories': [{'measurements': [{'value': '12.8', 'groupId': 'OG000', 'lowerLimit': '8.4', 'upperLimit': '18.3'}]}]}, {'title': 'Once a week: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '17.2', 'groupId': 'OG000', 'lowerLimit': '11.6', 'upperLimit': '24.2'}]}]}, {'title': 'Twice a week: Baseline (n=196)', 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.1'}]}]}, {'title': 'Twice a week: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000', 'lowerLimit': '0.4', 'upperLimit': '5.7'}]}]}, {'title': 'Three times a week: Baseline (n=196)', 'categories': [{'measurements': [{'value': '1.0', 'groupId': 'OG000', 'lowerLimit': '0.1', 'upperLimit': '3.6'}]}]}, {'title': 'Three times a week: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '0.7', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '3.6'}]}]}, {'title': 'Other: Baseline (n=196)', 'categories': [{'measurements': [{'value': '3.1', 'groupId': 'OG000', 'lowerLimit': '1.1', 'upperLimit': '6.5'}]}]}, {'title': 'Other: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '7.3', 'groupId': 'OG000', 'lowerLimit': '3.7', 'upperLimit': '12.7'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Month 6', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked "Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?". Participants answered as either once a month, twice a month, once a week, twice a week, three times a week or other (any other frequency). Percentage of participants with each preferred treatment frequency was reported.', 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants by Preferred Treatment Frequency by ESA Type', 'denoms': [{'units': 'Participants', 'counts': [{'value': '196', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Mircera: Once a month: Baseline (n=101)', 'categories': [{'measurements': [{'value': '83.2', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Once a month: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '75.8', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Twice a month: Baseline (n=101)', 'categories': [{'measurements': [{'value': '14.9', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Twice a month: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '15.2', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Once a week: Baseline (n=101)', 'categories': [{'measurements': [{'value': '1.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Once a week: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '3.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Twice a week: Baseline (n=101)', 'categories': [{'measurements': [{'value': '1.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Twice a week: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Three times a week: Baseline (n=101)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Three times a week: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Other: Baseline (n=101)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Other: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '6.1', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Once a month: Baseline (n=34)', 'categories': [{'measurements': [{'value': '44.1', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Once a month: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '27.6', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Twice a month: Baseline (n=34)', 'categories': [{'measurements': [{'value': '14.7', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Twice a month: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '31.0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Once a week: Baseline (n=34)', 'categories': [{'measurements': [{'value': '35.3', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Once a week: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '31.0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Twice a week: Baseline (n=34)', 'categories': [{'measurements': [{'value': '2.9', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Twice a week: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '6.9', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Three times a week: Baseline (n=34)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Three times a week: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '3.4', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Other: Baseline (n=34)', 'categories': [{'measurements': [{'value': '2.9', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Other: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Once a month: Baseline (n=21)', 'categories': [{'measurements': [{'value': '33.3', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Once a month: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '10.5', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Twice a month: Baseline (n=21)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Twice a month: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '15.8', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Once a week: Baseline (n=21)', 'categories': [{'measurements': [{'value': '42.9', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Once a week: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '52.6', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Twice a week: Baseline (n=21)', 'categories': [{'measurements': [{'value': '9.5', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Twice a week: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '5.3', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Three times a week: Baseline (n=21)', 'categories': [{'measurements': [{'value': '4.8', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Three times a week: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Other: Baseline (n=21)', 'categories': [{'measurements': [{'value': '9.5', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Other: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '15.8', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Once a month: Baseline (n=40)', 'categories': [{'measurements': [{'value': '47.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Once a month: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '37.8', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Twice a month: Baseline (n=40)', 'categories': [{'measurements': [{'value': '35.0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Twice a month: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '37.8', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Once a week: Baseline (n=40)', 'categories': [{'measurements': [{'value': '7.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Once a week: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '13.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Twice a week: Baseline (n=40)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Twice a week: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Three times a week: Baseline (n=40)', 'categories': [{'measurements': [{'value': '2.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Three times a week: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Other: Baseline (n=40)', 'categories': [{'measurements': [{'value': '7.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Other: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '10.8', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Month 6', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and their preference of treatment frequency. Participants were asked "Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?". Participants answered as either once a month, twice a month, once a week, twice a week, three times a week or other (any other frequency). Percentage of participants with each preferred treatment frequency and ESA type was reported.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "All enrolled participants. Here 'n' signifies number of participants evaluable for specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency', 'denoms': [{'units': 'Participants', 'counts': [{'value': '195', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Preferred O/M: Baseline ESA T/W: Baseline (n=5)', 'categories': [{'measurements': [{'value': '80.0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/M: Baseline ESA T/W: Month 6 (n=2)', 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/M: Baseline ESA B/W: Baseline (n=14)', 'categories': [{'measurements': [{'value': '28.6', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/M: Baseline ESA B/W: Month 6 (n=6)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/M: Baseline ESA O/W: Baseline (n=29)', 'categories': [{'measurements': [{'value': '27.6', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/M: Baseline ESA O/W: Month 6 (n=24)', 'categories': [{'measurements': [{'value': '12.5', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/M: Baseline ESA Q2W: Baseline (n=51)', 'categories': [{'measurements': [{'value': '49.0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/M: Baseline ESA Q2W: Month 6 (n=38)', 'categories': [{'measurements': [{'value': '13.2', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/M: Baseline ESA Q4W: Baseline (n=75)', 'categories': [{'measurements': [{'value': '98.7', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/M: Baseline ESA Q4W: Month 6 (n=59)', 'categories': [{'measurements': [{'value': '96.6', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/M: Baseline ESA other: Baseline (n=21)', 'categories': [{'measurements': [{'value': '47.6', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/M: Baseline ESA other: Month 6 (n=22)', 'categories': [{'measurements': [{'value': '36.4', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/M: Baseline ESA T/W: Baseline (n=5)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/M: Baseline ESA T/W: Month 6 (n=2)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/M: Baseline ESA B/W: Baseline (n=14)', 'categories': [{'measurements': [{'value': '28.6', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/M: Baseline ESA B/W: Month 6 (n=6)', 'categories': [{'measurements': [{'value': '33.3', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/M: Baseline ESA O/W: Baseline (n=29)', 'categories': [{'measurements': [{'value': '10.3', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/M: Baseline ESA O/W: Month 6 (n=24)', 'categories': [{'measurements': [{'value': '8.3', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/M: Baseline ESA Q2W: Baseline (n=51)', 'categories': [{'measurements': [{'value': '47.1', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/M: Baseline ESA Q2W: Month 6 (n=38)', 'categories': [{'measurements': [{'value': '81.6', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/M: Baseline ESA Q4W: Baseline (n=75)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/M: Baseline ESA Q4W: Month 6 (n=59)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/M: Baseline ESA other: Baseline (n=21)', 'categories': [{'measurements': [{'value': '9.5', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/M: Baseline ESA other: Month 6 (n=22)', 'categories': [{'measurements': [{'value': '4.5', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/W: Baseline ESA T/W: Baseline (n=5)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/W: Baseline ESA T/W: Month 6 (n=2)', 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/W: Baseline ESA B/W: Baseline (n=14)', 'categories': [{'measurements': [{'value': '28.6', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/W: Baseline ESA B/W: Month 6 (n=6)', 'categories': [{'measurements': [{'value': '33.3', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/W: Baseline ESA O/W: Baseline (n=29)', 'categories': [{'measurements': [{'value': '62.1', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/W: Baseline ESA O/W: Month 6 (n=24)', 'categories': [{'measurements': [{'value': '79.2', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/W: Baseline ESA Q2W: Baseline (n=51)', 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/W: Baseline ESA Q2W: Month 6 (n=38)', 'categories': [{'measurements': [{'value': '2.6', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/W: Baseline ESA Q4W: Baseline (n=75)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/W: Baseline ESA Q4W: Month 6 (n=59)', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/W: Baseline ESA other: Baseline (n=21)', 'categories': [{'measurements': [{'value': '9.5', 'groupId': 'OG000'}]}]}, {'title': 'Preferred O/W: Baseline ESA other: Month 6 (n=22)', 'categories': [{'measurements': [{'value': '9.1', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/W: Baseline ESA T/W: Baseline (n=5)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/W: Baseline ESA T/W: Month 6 (n=2)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/W: Baseline ESA B/W: Baseline (n=14)', 'categories': [{'measurements': [{'value': '14.3', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/W: Baseline ESA B/W: Month 6 (n=6)', 'categories': [{'measurements': [{'value': '33.3', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/W: Baseline ESA O/W: Baseline (n=29)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/W: Baseline ESA O/W: Month 6 (n=24)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/W: Baseline ESA Q2W: Baseline (n=51)', 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/W: Baseline ESA Q2W: Month 6 (n=38)', 'categories': [{'measurements': [{'value': '2.6', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/W: Baseline ESA Q4W: Baseline (n=75)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/W: Baseline ESA Q4W: Month 6 (n=59)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/W: ESA other: Baseline (n=21)', 'categories': [{'measurements': [{'value': '4.8', 'groupId': 'OG000'}]}]}, {'title': 'Preferred B/W: ESA other: Month 6 (n=22)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred T/W: Baseline ESA T/W: Baseline (n=5)', 'categories': [{'measurements': [{'value': '20.0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred T/W: Baseline ESA T/W: Month 6 (n=2)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred T/W: Baseline ESA B/W: Baseline (n=14)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred T/W: Baseline ESA B/W: Month 6 (n=6)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred T/W: Baseline ESA O/W: Baseline (n=29)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred T/W: Baseline ESA O/W: Month 6 (n=24)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred T/W: Baseline ESA Q2W: Baseline (n=51)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred T/W: Baseline ESA Q2W: Month 6 (n=38)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred T/W: Baseline ESA Q4W: Baseline (n=75)', 'categories': [{'measurements': [{'value': '1.3', 'groupId': 'OG000'}]}]}, {'title': 'Preferred T/W: Baseline ESA Q4W: Month 6 (n=59)', 'categories': [{'measurements': [{'value': '1.7', 'groupId': 'OG000'}]}]}, {'title': 'Preferred T/W: Baseline ESA other: Baseline (n=21)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred T/W: Baseline ESA other: Month 6 (n=22)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred Other: Baseline ESA T/W: Baseline (n=5)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred Other: Baseline ESA T/W: Month 6 (n=2)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred Other: Baseline ESA B/W: Baseline (n=14)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred Other: Baseline ESA B/W: Month 6 (n=6)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred Other: Baseline ESA O/W: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred Other: Baseline ESA O/W: Month 6 (n=24)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred Other: Baseline ESA Q2W: Baseline (n=51)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred Other: Baseline ESA Q2W: Month 6 (n=38)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred Other: Baseline ESA Q4W: Baseline (n=75)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred Other: Baseline ESA Q4W: Month 6 (n=59)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Preferred Other:Baseline ESA other:Baseline (n=21)', 'categories': [{'measurements': [{'value': '28.6', 'groupId': 'OG000'}]}]}, {'title': 'Preferred Other:Baseline ESA other: Month 6 (n=22)', 'categories': [{'measurements': [{'value': '50.0', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Month 6', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for their preference of treatment frequency and baseline ESA frequency. Participants were asked "Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?". Preferred treatment frequency included: once a month (O/M), twice a month (B/M), once a week (O/W), twice a week (B/W), three times a week (T/W) or other (any other frequency\\]). Frequency of baseline ESA use included: three times a week, twice a week, once a week, every 2 weeks (Q2W), every 4 weeks (Q4W) or other (any other frequency). Percentage of participants by each preferred treatment frequency and baseline ESA frequency was reported.', 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "All enrolled participants. Number of participants analyzed = participants evaluable for this outcome measure. Here 'n' signifies number of participants evaluable for specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements', 'denoms': [{'units': 'Participants', 'counts': [{'value': '196', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Score 1: Baseline (n=196)', 'categories': [{'measurements': [{'value': '96.4', 'groupId': 'OG000', 'lowerLimit': '92.8', 'upperLimit': '98.6'}]}]}, {'title': 'Score 1: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '97.4', 'groupId': 'OG000', 'lowerLimit': '93.4', 'upperLimit': '99.3'}]}]}, {'title': 'Score 2: Baseline (n=196)', 'categories': [{'measurements': [{'value': '1.0', 'groupId': 'OG000', 'lowerLimit': '0.1', 'upperLimit': '3.6'}]}]}, {'title': 'Score 2: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '0.7', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '3.6'}]}]}, {'title': 'Score 3: Baseline (n=196)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '0'}]}]}, {'title': 'Score 3: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '1.3', 'groupId': 'OG000', 'lowerLimit': '0.2', 'upperLimit': '4.7'}]}]}, {'title': 'Score 4: Baseline (n=196)', 'categories': [{'measurements': [{'value': '0.5', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '2.8'}]}]}, {'title': 'Score 4: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '0'}]}]}, {'title': 'Score 5: Baseline (n=196)', 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.1'}]}]}, {'title': 'Score 5: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '0.7', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '3.6'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their limitation of daily life due to ESA refrigeration requirements on a 1-5 scale, where 1 represents 'Does not limit' and 5 represents 'significantly limits'. Percentage of participants with each score was reported.", 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types', 'denoms': [{'units': 'Participants', 'counts': [{'value': '196', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Mircera: Score 1: Baseline (n=101)', 'categories': [{'measurements': [{'value': '97.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 2: Baseline (n=101)', 'categories': [{'measurements': [{'value': '1.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 4: Baseline (n=101)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 5: Baseline (n=101)', 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 1: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 2: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 3: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 5: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 1: Baseline (n=34)', 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 2: Baseline (n=34', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 4: Baseline (n=34', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 5: Baseline (n=34', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 1: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '96.6', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 2: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '3.4', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 3: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 5: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 1: Baseline (n=21)', 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 2: Baseline (n=21)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 4: Baseline (n=21)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 5: Baseline (n=21)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 1: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '94.7', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 2: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 3: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 5: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '5.3', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 1: Baseline (n=40)', 'categories': [{'measurements': [{'value': '90.0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 2: Baseline (n=40)', 'categories': [{'measurements': [{'value': '2.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 4: Baseline (n=40)', 'categories': [{'measurements': [{'value': '2.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 5: Baseline (n=40)', 'categories': [{'measurements': [{'value': '5.0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 1: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '94.6', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 2: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 3: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '5.4', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 5: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their limitation of daily life due to ESA refrigeration requirements on a 1-5 scale, where 1 represents 'Does not limit' and 5 represents 'significantly limits'. Percentage of participants with each score and ESA type was reported.", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "All enrolled participants. Here 'n' signifies number of participants evaluable for specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants by Convenience of Syringe Usage', 'denoms': [{'units': 'Participants', 'counts': [{'value': '196', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Score 1: Baseline (n=196)', 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000', 'lowerLimit': '0.6', 'upperLimit': '5.1'}]}]}, {'title': 'Score 3: Baseline (n=196)', 'categories': [{'measurements': [{'value': '2.6', 'groupId': 'OG000', 'lowerLimit': '0.8', 'upperLimit': '5.9'}]}]}, {'title': 'Score 4: Baseline (n=196)', 'categories': [{'measurements': [{'value': '6.6', 'groupId': 'OG000', 'lowerLimit': '3.6', 'upperLimit': '11.1'}]}]}, {'title': 'Score 5: Baseline (n=196)', 'categories': [{'measurements': [{'value': '88.8', 'groupId': 'OG000', 'lowerLimit': '83.5', 'upperLimit': '92.8'}]}]}, {'title': 'Score 1: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '0.7', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '3.6'}]}]}, {'title': 'Score 3: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '2.0', 'groupId': 'OG000', 'lowerLimit': '0.4', 'upperLimit': '5.7'}]}]}, {'title': 'Score 4: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '4.0', 'groupId': 'OG000', 'lowerLimit': '1.5', 'upperLimit': '8.4'}]}]}, {'title': 'Score 5: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '93.4', 'groupId': 'OG000', 'lowerLimit': '88.2', 'upperLimit': '96.8'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their convenience of syringe usage on a 1-5 scale, where 1 represents 'Inconvenient' and 5 represents 'Very convenient'. Percentage of participants with each score was reported.", 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants by Convenience of Syringe Usage by ESA Type', 'denoms': [{'units': 'Participants', 'counts': [{'value': '196', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Mircera: Score 1: Baseline (n=101)', 'categories': [{'measurements': [{'value': '4.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 3: Baseline (n=101)', 'categories': [{'measurements': [{'value': '1.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 4: Baseline (n=101)', 'categories': [{'measurements': [{'value': '5.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 5: Baseline (n=101)', 'categories': [{'measurements': [{'value': '90.1', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 1: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 3: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 4: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '1.5', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 5: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '98.5', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 1: Baseline (n=34)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 3: Baseline (n=34)', 'categories': [{'measurements': [{'value': '2.9', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 4: Baseline (n=34)', 'categories': [{'measurements': [{'value': '11.8', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 5: Baseline (n=34)', 'categories': [{'measurements': [{'value': '85.3', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 1: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 3: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '3.4', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 4: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '6.9', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 5: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '89.7', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 1: Baseline (n=21)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 3: Baseline (n=21)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 4: Baseline (n=21)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 5: Baseline (n=21)', 'categories': [{'measurements': [{'value': '100.0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 1: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '5.3', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 3: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '5.3', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 4: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 5: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '89.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 1: Baseline (n=40)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 3: Baseline (n=40)', 'categories': [{'measurements': [{'value': '7.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 4: Baseline (n=40)', 'categories': [{'measurements': [{'value': '10.0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 5: Baseline (n=40)', 'categories': [{'measurements': [{'value': '82.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 1: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 3: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '2.7', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 4: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '8.1', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 5: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '89.2', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their convenience of syringe usage on a 1-5 scale, where 1 represents 'Inconvenient' and 5 represents 'Very convenient'. Percentage of participants with each score and ESA type was reported.", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "All enrolled participants. Here 'n' signifies number of participants evaluable for specified categories."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants by Injection Site Pain', 'denoms': [{'units': 'Participants', 'counts': [{'value': '196', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Score 1: Baseline (n=196)', 'categories': [{'measurements': [{'value': '88.8', 'groupId': 'OG000', 'lowerLimit': '83.5', 'upperLimit': '92.8'}]}]}, {'title': 'Score 1: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '92.1', 'groupId': 'OG000', 'lowerLimit': '86.5', 'upperLimit': '95.8'}]}]}, {'title': 'Score 2: Baseline (n=196)', 'categories': [{'measurements': [{'value': '8.2', 'groupId': 'OG000', 'lowerLimit': '4.7', 'upperLimit': '12.9'}]}]}, {'title': 'Score 2: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '6.0', 'groupId': 'OG000', 'lowerLimit': '2.8', 'upperLimit': '11.0'}]}]}, {'title': 'Score 3: Baseline (n=196)', 'categories': [{'measurements': [{'value': '1.5', 'groupId': 'OG000', 'lowerLimit': '0.3', 'upperLimit': '4.4'}]}]}, {'title': 'Score 3: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '1.3', 'groupId': 'OG000', 'lowerLimit': '0.2', 'upperLimit': '4.7'}]}]}, {'title': 'Score 4: Baseline (n=196)', 'categories': [{'measurements': [{'value': '0.5', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '2.8'}]}]}, {'title': 'Score 4: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '0.7', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '3.6'}]}]}, {'title': 'Score 5: Baseline (n=196)', 'categories': [{'measurements': [{'value': '1.0', 'groupId': 'OG000', 'lowerLimit': '0.1', 'upperLimit': '3.6'}]}]}, {'title': 'Score 5: Month 6 (n=151)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000', 'lowerLimit': '0', 'upperLimit': '0'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their injection site pain on a 1-5 scale, where 1 represents 'Not painful' and 5 represents 'Very painful'. Percentage of participants with each score was reported.", 'unitOfMeasure': 'percentage of participants', 'dispersionType': '95% Confidence Interval', 'reportingStatus': 'POSTED', 'populationDescription': "All enrolled participants. Here 'n' signifies number of participants evaluable at specified time-points."}, {'type': 'SECONDARY', 'title': 'Percentage of Participants by Injection Site Pain by ESA Type', 'denoms': [{'units': 'Participants', 'counts': [{'value': '196', 'groupId': 'OG000'}]}], 'groups': [{'id': 'OG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'classes': [{'title': 'Mircera: Score 1: Baseline (n=101)', 'categories': [{'measurements': [{'value': '92.1', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 2: Baseline (n=101)', 'categories': [{'measurements': [{'value': '6.9', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 3: Baseline (n=101)', 'categories': [{'measurements': [{'value': '1.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 4: Baseline (n=101)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 5: Baseline (n=101)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 1: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '97.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 2: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '3.0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 3: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Mircera: Score 4: Month 6 (n=66)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 1: Baseline (n=34)', 'categories': [{'measurements': [{'value': '91.2', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 2: Baseline (n=34', 'categories': [{'measurements': [{'value': '5.9', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 3: Baseline (n=34)', 'categories': [{'measurements': [{'value': '2.9', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 4: Baseline (n=34)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 5: Baseline (n=34)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 1: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '96.6', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 2: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '3.4', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 3: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Recormon: Score 4: Month 6 (n=29)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 1: Baseline (n=21)', 'categories': [{'measurements': [{'value': '71.4', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 2: Baseline (n=21)', 'categories': [{'measurements': [{'value': '23.8', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 3: Baseline (n=21)', 'categories': [{'measurements': [{'value': '4.8', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 4: Baseline (n=21)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 5: Baseline (n=21)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 1: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '84.2', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 2: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '15.8', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 3: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Eprex: Score 4: Month 6 (n=19)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 1: Baseline (n=40)', 'categories': [{'measurements': [{'value': '87.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 2: Baseline (n=40)', 'categories': [{'measurements': [{'value': '5.0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 3: Baseline (n=40)', 'categories': [{'measurements': [{'value': '0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 4: Baseline (n=40)', 'categories': [{'measurements': [{'value': '2.5', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 5: Baseline (n=40)', 'categories': [{'measurements': [{'value': '5.0', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 1: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '83.8', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 2: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '8.1', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 3: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '5.4', 'groupId': 'OG000'}]}]}, {'title': 'Aranesp: Score 4: Month 6 (n=37)', 'categories': [{'measurements': [{'value': '2.7', 'groupId': 'OG000'}]}]}], 'paramType': 'NUMBER', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their injection site pain on a 1-5 scale, where 1 represents 'Not painful' and 5 represents 'Very painful'. Percentage of participants with each score and ESA type was reported.", 'unitOfMeasure': 'percentage of participants', 'reportingStatus': 'POSTED', 'populationDescription': "All enrolled participants. Here 'n' signifies number of participants evaluable for specified categories."}]}, 'participantFlowModule': {'groups': [{'id': 'FG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with Chronic Kidney Disease (CKD) who were not on dialysis and treated with Erythropoiesis-Stimulating Agents (ESA) according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'periods': [{'title': 'Overall Study', 'milestones': [{'type': 'STARTED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '196'}]}, {'type': 'COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '151'}]}, {'type': 'NOT COMPLETED', 'achievements': [{'groupId': 'FG000', 'numSubjects': '45'}]}], 'dropWithdraws': [{'type': 'Not completed survey at Month 6', 'reasons': [{'groupId': 'FG000', 'numSubjects': '45'}]}]}]}, 'baselineCharacteristicsModule': {'denoms': [{'units': 'Participants', 'counts': [{'value': '196', 'groupId': 'BG000'}]}], 'groups': [{'id': 'BG000', 'title': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who were not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, were interviewed by physician who completed the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.'}], 'measures': [{'title': 'Age, Continuous', 'classes': [{'categories': [{'measurements': [{'value': '74.6', 'spread': '10.6', 'groupId': 'BG000'}]}]}], 'paramType': 'MEAN', 'unitOfMeasure': 'years', 'dispersionType': 'STANDARD_DEVIATION'}, {'title': 'Sex: Female, Male', 'classes': [{'categories': [{'title': 'Female', 'measurements': [{'value': '85', 'groupId': 'BG000'}]}, {'title': 'Male', 'measurements': [{'value': '111', 'groupId': 'BG000'}]}]}], 'paramType': 'COUNT_OF_PARTICIPANTS', 'unitOfMeasure': 'Participants'}], 'populationDescription': 'All enrolled participants'}}, 'protocolSection': {'designModule': {'studyType': 'OBSERVATIONAL', 'designInfo': {'timePerspective': 'CROSS_SECTIONAL', 'observationalModel': 'COHORT'}, 'enrollmentInfo': {'type': 'ACTUAL', 'count': 196}}, 'statusModule': {'overallStatus': 'COMPLETED', 'startDateStruct': {'date': '2011-09'}, 'expandedAccessInfo': {'hasExpandedAccess': False}, 'statusVerifiedDate': '2017-02', 'completionDateStruct': {'date': '2013-08', 'type': 'ACTUAL'}, 'lastUpdateSubmitDate': '2017-02-21', 'studyFirstSubmitDate': '2014-09-10', 'resultsFirstSubmitDate': '2016-09-16', 'studyFirstSubmitQcDate': '2014-09-10', 'lastUpdatePostDateStruct': {'date': '2017-03-24', 'type': 'ACTUAL'}, 'resultsFirstSubmitQcDate': '2016-09-16', 'studyFirstPostDateStruct': {'date': '2014-09-12', 'type': 'ESTIMATED'}, 'resultsFirstPostDateStruct': {'date': '2016-11-07', 'type': 'ESTIMATED'}, 'primaryCompletionDateStruct': {'date': '2013-08', 'type': 'ACTUAL'}}, 'outcomesModule': {'primaryOutcomes': [{'measure': 'Percentage of Participants by ESA Types at Baseline', 'timeFrame': 'Baseline', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type was reported.'}, {'measure': 'Percentage of Participants by ESA Types at Month 6', 'timeFrame': 'Month 6', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type was reported.'}, {'measure': 'Percentage of Participants by Frequency of ESA Use at Baseline', 'timeFrame': 'Baseline', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). Percentage of participants by each frequency of ESA use was reported.'}, {'measure': 'Percentage of Participants by Frequency of ESA Use at Month 6', 'timeFrame': 'Month 6', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). Percentage of participants by each frequency of ESA use was reported.'}, {'measure': 'Percentage of Participants by Frequency and Types of ESA Used at Baseline', 'timeFrame': 'Baseline', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type and each frequency of ESA use was reported.'}, {'measure': 'Percentage of Participants by Frequency and Types of ESA Used at Month 6', 'timeFrame': 'Month 6', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. Frequency of ESA use included:Three times a week, twice a week, once a week, every 2 weeks, every 4 weeks or other (any other frequency). ESA types included: Mircera, Recormon, Eprex, and Aranesp. Percentage of participants with each ESA type and each frequency of ESA use was reported.'}], 'secondaryOutcomes': [{'measure': 'Percentage of Participants by Different CKD Stages', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. CKD stages were based on participant's answer to the survey question. No specific method of assessment for CKD stage was specified. Percentage of participants with each CKD stage was reported."}, {'measure': 'Percentage of Participants by Different Injection Administration Modes', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked: 'How do you currently inject the anemia treatment?' and reported any of the 5 possible answers: Independently, by a family member, nurse at home, nurse at the clinic or other. Percentage of participants with each injection administration modes was reported."}, {'measure': 'Percentage of Participants With Interest in Learning to Inject Independently', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants responded 'yes' or 'no' to the question: 'Would you be interested in learning to inject independently?' ' Percentage of participants who responded 'yes', was reported."}, {'measure': 'Percentage of Participants by Need for Improvement in Treatment Frequency', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their need for improvement in the frequency of treatment received currently on a 1-5 scale, where 1 represents 'Convenient, there is no need for improvement' and 5 represents 'Improvement is very necessary'. Percentage of participants with each score was reported."}, {'measure': 'Percentage of Participants by Need for Improvement in Treatment Frequency by ESA Type', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their need for improvement in the frequency of each treatment received currently on a 1-5 scale, where 1 represents 'Convenient, there is no need for improvement' and 5 represents 'improvement is very necessary'. Percentage of participants with each score and ESA type was reported."}, {'measure': 'Percentage of Participants by Preferred Treatment Frequency', 'timeFrame': 'Baseline, Month 6', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked "Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?". Participants answered as either once a month, twice a month, once a week, twice a week, three times a week or other (any other frequency). Percentage of participants with each preferred treatment frequency was reported.'}, {'measure': 'Percentage of Participants by Preferred Treatment Frequency by ESA Type', 'timeFrame': 'Baseline, Month 6', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and their preference of treatment frequency. Participants were asked "Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?". Participants answered as either once a month, twice a month, once a week, twice a week, three times a week or other (any other frequency). Percentage of participants with each preferred treatment frequency and ESA type was reported.'}, {'measure': 'Percentage of Participants by Preferred Treatment Frequency by Baseline ESA Frequency', 'timeFrame': 'Baseline, Month 6', 'description': 'Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for their preference of treatment frequency and baseline ESA frequency. Participants were asked "Assuming that there are several options for anemia treatment with the only difference being the frequency of use, what is your preference?". Preferred treatment frequency included: once a month (O/M), twice a month (B/M), once a week (O/W), twice a week (B/W), three times a week (T/W) or other (any other frequency\\]). Frequency of baseline ESA use included: three times a week, twice a week, once a week, every 2 weeks (Q2W), every 4 weeks (Q4W) or other (any other frequency). Percentage of participants by each preferred treatment frequency and baseline ESA frequency was reported.'}, {'measure': 'Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their limitation of daily life due to ESA refrigeration requirements on a 1-5 scale, where 1 represents 'Does not limit' and 5 represents 'significantly limits'. Percentage of participants with each score was reported."}, {'measure': 'Percentage of Participants by Limitation of Daily Life Due to ESA Refrigeration Requirements by ESA Types', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their limitation of daily life due to ESA refrigeration requirements on a 1-5 scale, where 1 represents 'Does not limit' and 5 represents 'significantly limits'. Percentage of participants with each score and ESA type was reported."}, {'measure': 'Percentage of Participants by Convenience of Syringe Usage', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their convenience of syringe usage on a 1-5 scale, where 1 represents 'Inconvenient' and 5 represents 'Very convenient'. Percentage of participants with each score was reported."}, {'measure': 'Percentage of Participants by Convenience of Syringe Usage by ESA Type', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their convenience of syringe usage on a 1-5 scale, where 1 represents 'Inconvenient' and 5 represents 'Very convenient'. Percentage of participants with each score and ESA type was reported."}, {'measure': 'Percentage of Participants by Injection Site Pain', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked to rate their injection site pain on a 1-5 scale, where 1 represents 'Not painful' and 5 represents 'Very painful'. Percentage of participants with each score was reported."}, {'measure': 'Percentage of Participants by Injection Site Pain by ESA Type', 'timeFrame': 'Baseline, Month 6', 'description': "Assessment was performed by physician via a satisfaction survey on anemia treatment. Participants were asked for the type of ESA received (Mircera, Recormon, Eprex or Aranesp) and to rate their injection site pain on a 1-5 scale, where 1 represents 'Not painful' and 5 represents 'Very painful'. Percentage of participants with each score and ESA type was reported."}]}, 'conditionsModule': {'conditions': ['Chronic Kidney Diseases']}, 'descriptionModule': {'briefSummary': "This study is a prospective, non-interventional, cross-sectional multicenter survey. The aim is to better understand the current therapy pattern for anemia in CKD treated with erythropoiesis-stimulating agents (ESAs) and not on-dialysis participant population in Israel. Participating physicians will be requested to interview eligible participants with CKD not on dialysis and to complete for them a satisfaction survey for anemia treatment. The survey will be completed twice, once at study start and once at six months' follow-up."}, 'eligibilityModule': {'sex': 'ALL', 'stdAges': ['ADULT', 'OLDER_ADULT'], 'minimumAge': '18 Years', 'samplingMethod': 'NON_PROBABILITY_SAMPLE', 'studyPopulation': 'Adult participants with CKD not on-dialysis treated with ESAs', 'healthyVolunteers': False, 'eligibilityCriteria': 'Inclusion Criteria:\n\n* Adult participants with CKD Stage 3-5\n* Treated with ESAs\n* Participant is speaking the same language as the investigator interviewer\n\nExclusion Criteria:\n\n* Past or current treatment with dialysis'}, 'identificationModule': {'nctId': 'NCT02238067', 'briefTitle': 'Survey on Anemia Therapy in Participants With Chronic Kidney Disease (CKD) Not on Dialysis', 'organization': {'class': 'INDUSTRY', 'fullName': 'Hoffmann-La Roche'}, 'officialTitle': 'Survey on Anemia Therapy With ESAs Medication in Chronic Kidney Disease Patients Not on Dialysis', 'orgStudyIdInfo': {'id': 'ML25473'}}, 'armsInterventionsModule': {'armGroups': [{'label': 'Chronic Renal Anemia Participants', 'description': 'Participants with CKD who are not on dialysis and treated with ESA according to the usual standard of care and best practice guidelines, will be interviewed by physician who will complete the satisfaction surveys on anemia treatment at baseline and at 6 months follow-up visit.', 'interventionNames': ['Drug: ESA', 'Other: Satisfaction Survey Questionnaire']}], 'interventions': [{'name': 'ESA', 'type': 'DRUG', 'description': "Participants will continue to receive their ESA treatment, as per physician's discretion. The study protocol does not specify any particular ESA drug.", 'armGroupLabels': ['Chronic Renal Anemia Participants']}, {'name': 'Satisfaction Survey Questionnaire', 'type': 'OTHER', 'description': 'Each participant will be interviewed to complete treatment satisfaction questionnaire survey at baseline and at 6-month follow-up visit.', 'armGroupLabels': ['Chronic Renal Anemia Participants']}]}, 'contactsLocationsModule': {'locations': [{'city': 'Ganey Tikva', 'country': 'Israel', 'facility': 'Clalit- New Savyon Clinic'}, {'city': 'Jerusalem', 'country': 'Israel', 'facility': 'Clalit - Diabetic HaMoshava South Clinic', 'geoPoint': {'lat': 31.76904, 'lon': 35.21633}}, {'city': 'Karmiel', 'country': 'Israel', 'facility': 'Clalit Carmiel', 'geoPoint': {'lat': 32.91708, 'lon': 35.30501}}, {'city': 'Kiryat Bialik', 'country': 'Israel', 'facility': 'Clalit - Professional Clinic, Zvulun', 'geoPoint': {'lat': 32.8275, 'lon': 35.08583}}, {'city': 'Naẕerat ‘Illit', 'country': 'Israel', 'facility': 'Clalit Ben-Gurion', 'geoPoint': {'lat': 32.70816, 'lon': 35.32469}}, {'zip': '76100', 'city': 'Rehovot', 'country': 'Israel', 'facility': 'Kaplan Medical Center; Nephrology and Hypertension Services', 'geoPoint': {'lat': 31.89421, 'lon': 34.81199}}, {'city': 'Tel Aviv', 'country': 'Israel', 'facility': 'Clalit- Migdal HaMea Clinic, Tel Aviv', 'geoPoint': {'lat': 32.08088, 'lon': 34.78057}}], 'overallOfficials': [{'name': 'Clinical Trials', 'role': 'STUDY_DIRECTOR', 'affiliation': 'Hoffmann-La Roche'}]}, 'sponsorCollaboratorsModule': {'leadSponsor': {'name': 'Hoffmann-La Roche', 'class': 'INDUSTRY'}, 'responsibleParty': {'type': 'SPONSOR'}}}}